Raymond James initiated coverage of Omega Therapeutics with an Outperform rating and $12 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMGA:
- Omega Therapeutics Appoints New Chief Business Officer
- Omega Therapeutics To Participate In Two Upcoming Investor Conferences
- Omega Therapeutics appoints Certel as Chief Business Officer
- Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
- Omega Therapeutics presents new preclinical data at ASGCT 2024